Agenus Inc. - Special Call Transcript
Good afternoon, ladies and gentlemen, and welcome to the next-generation immuno-oncology therapeutics conference call. (Operator Instructions)
It is now my pleasure to turn the floor over to your host, Mayank Mamtani. Sir, the floor is yours.
Thank you, John. Hello, good evening, everyone. This is Mayank Mamtani, I'm a senior analyst covering biotechnology companies at B. Riley FBR. I hope everyone is keeping well and thanks for joining. I'm pleased to welcome you to our expert panel call today to recap an exciting data at ASCO weekend, in particular focusing on next-generation CTLA-4 agents where we saw Agenus present encouraging early data as monotherapy and in combination with PD-1. We have with us on the call, Dr. Steven O'Day, who were the leading clinical investigator who presented that data, and also Dr. Charles Drake, who have -- and both of these guys had -- obviously don't need introduction, but they've obviously pioneered the checkpoint inhibitor biology space over the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
